Research and development

Itronics Positioned to Benefit From Historic High and Rising Gold Prices

Retrieved on: 
Thursday, April 4, 2024
Tin, Silver, Transport, Zinc, Gold, Clean technology, Metal, Copper, Lead, Geology, United, Mineral, Research and development, Mining, OTC, Intellectual property, Probability, ITRO, Economics, Fertilizer, Iron

Gold, silver, and other precious metals have made a sustained push toward historically high prices over the last several months.

Key Points: 
  • Gold, silver, and other precious metals have made a sustained push toward historically high prices over the last several months.
  • Itronics is currently engaged in three significant technology areas enhancing non-cyanide gold recovery, alongside a technique to improve cyanide-based heap leach gold recovery processes.
  • This is an Itronics technology advantage that provides a measurable economic benefit and increases the significance of rising gold and silver prices.
  • “By leveraging its ability to maximize the recovery of value from metals resources, Itronics, its clients, and its investors stand to benefit greatly by the historic rise in gold prices,” said Itronics President Dr. John Whitney.

INOD Investors: Pending Lead Plaintiff Deadline of April 22, 2024 is Quickly Approaching in the Innodata Inc. Class Action; Contact Robbins LLP for Information

Retrieved on: 
Wednesday, April 3, 2024
Research, SAN, News, LLP, AI, Nature, Silicon, Complaint, Goldengate, Research and development, Wolfpack, Marketing

Plaintiffs allege that on February 15, 2024, Wolfpack Research published a report revealing that Innodata misrepresented the nature and extent of its business and operations.

Key Points: 
  • Plaintiffs allege that on February 15, 2024, Wolfpack Research published a report revealing that Innodata misrepresented the nature and extent of its business and operations.
  • The Company also stopped disclosing its Research and Development (R&D) spend after the first quarter of 2021.
  • What Now: You may be eligible to participate in the class action against Innodata Inc. Shareholders who want to serve as lead plaintiff for the class must file their papers with the court by April 22, 2024.
  • A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Innodata

Retrieved on: 
Wednesday, April 3, 2024
Research, Growth, Defendant, News, LLP, AI, Nature, Silicon, Goldengate, Research and development, Advertising, Wolfpack, Marketing, Court, Cryptocurrency

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points: 
  • Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Innodata’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ).

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against NYCB, InMode, Innodata, and Fox Factory and Encourages Investors to Contact the Firm

Retrieved on: 
Wednesday, April 3, 2024
Research, Class Action, Signature, Growth, ACL, Food and Drug Administration, Defendant, Dermatology, News, AI, New York Community Bank, Nature, NYCB, Silicon, Complaint, P.C, Goldengate, Research and development, Fox Factory, Assumption, Confidentiality, Injury, Category, Wolfpack, Dentist, FDA, Marketing

NYCB is a large commercial-real estate lender in the New York City market area, where it specializes in rent-regulated, non-luxury apartment buildings.

Key Points: 
  • NYCB is a large commercial-real estate lender in the New York City market area, where it specializes in rent-regulated, non-luxury apartment buildings.
  • On January 31, 2024, before the market opened, NYCB announced its fiscal fourth quarter 2023 financial results.
  • The complaint further alleges that when these misleading statements and omissions about Fox Factory’s business reached the market, investors were harmed significantly.
  • For more information on the Fox Factory class action go to: https://bespc.com/cases/FOXF

Locafy Reports Fiscal First Half 2024 Results

Retrieved on: 
Tuesday, April 2, 2024
Shift, Database, Platform, Partnership, Travel, KPI, MRR, Depreciation, Research and development, Ecosystem, Optimism, Advertising, Marketing, Directory, Video game

PERTH, Australia, April 02, 2024 (GLOBE NEWSWIRE) -- Locafy Limited (Nasdaq: LCFY, LCFYW) (“Locafy” or the “Company”), a globally recognized software-as-a-service technology company specializing in local search engine marketing, today reported financial results for the 2024 fiscal first half ended December 31, 2023. All financial results are reported in Australian Dollars (AUD).

Key Points: 
  • “Our 2024 fiscal first half presented several promising opportunities for our business that inform our optimism for the rest of the fiscal year,” said Locafy CEO Gavin Burnett.
  • We look forward to providing updates in the coming quarters.”
    Results compare the 2024 fiscal first half end (December 31, 2023) to the 2023 fiscal first half end (December 31, 2022) unless otherwise indicated.
  • This increase is mainly due to the higher starting cost base of capitalized development cost for fiscal 2024 compared to fiscal 2023.
  • Monthly recurring revenue (MRR) for the 2024 fiscal second quarter was $314,000, a 32.2% decrease compared to $464,000 for the comparable year-ago period, and a 12.5% decrease compared to $360,000 for the 2024 fiscal first quarter.

Teleflex Incorporated Introduces the UroLift™ 2 System With Advanced Tissue Control, a Revolutionary Unified Platform Designed to Treat All Prostate Types

Retrieved on: 
Tuesday, April 2, 2024
Urology, TFX, Development, Anatomy, ATC, Patient, Research and development, BPH, FDA, Physician, Medical imaging

The UroLift™ 2 System with Advanced Tissue Control (UroLift™ 2 ATC) has received FDA clearance, marking a significant advancement in BPH care.

Key Points: 
  • The UroLift™ 2 System with Advanced Tissue Control (UroLift™ 2 ATC) has received FDA clearance, marking a significant advancement in BPH care.
  • Bringing the enhanced tissue control capabilities onto the innovative and proven UroLift™ 2 platform allows me to deliver unparalleled precision to treat a broad spectrum of patients and anatomies.
  • It has transformed my approach to BPH care,” said Dr. Adam Craig Thomas of Parkview Physicians Group Urology in Fort Wayne, Indiana.
  • It ensures I’m always equipped to treat a broad range of patients with unique prostate types and anatomies.”
    To learn more about UroLift™ 2 ATC, visit UroLift.com .

Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

Retrieved on: 
Monday, April 1, 2024
Diagnosis, Research, Week, CD135, Administration, FMS, Growth, Menin, CLL, NSCLC, C-peptide, AML, BID, Diabetes, Insulin, Patient, Hypoglycemia, FLT3, G&A, Acute myeloid leukemia, Food, PDAC, Health Canada, Trial of the century, IND, Cancer, CRC, Safety, Research and development, Investment, FDA, DLBCL, DSM-IV codes, Pharmaceutical industry

In 2023, initiated a Phase 2 study of BMF-219 in type 1 diabetes patients (COVALENT-112); initial readout anticipated in 2024.

Key Points: 
  • In 2023, initiated a Phase 2 study of BMF-219 in type 1 diabetes patients (COVALENT-112); initial readout anticipated in 2024.
  • Cash position of $177.2 million at the end of the fourth quarter of 2023.
  • REDWOOD CITY, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “the Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with metabolic diseases and genetically defined cancers, reported fourth quarter and full year 2023 financial results and corporate highlights.
  • “2023 was a pivotal year for Biomea as we reported first positive data in type 2 diabetes and initiated our first clinical study in type 1 diabetes.

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Monday, April 1, 2024
Lewy body, Research, GBA, Administration, Plasma, Conference, MRI, DLB, GFAP, Basal forebrain, Patient, Journal, Chairperson, Sale, TID, Manuscript, Public expenditure, Biomarker, Glial fibrillary acidic protein, MD, University College London, Atrophy, Publication, Frontotemporal dementia, Alpha-synuclein, NIA, Research and development, Vertex Pharmaceuticals, Axonal transport, Dementia, CRVO

BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today reported its financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Moreover, the neflamapimod treatment effects on GFAP were correlated to clinical outcomes, assessed by the CDR-SB.
  • Cash Position: As of December 31, 2023, CervoMed had $7.8 million in cash and cash equivalents as compared to $4.1 million as of December 31, 2022.
  • This increase was attributed to the RewinD-LB Phase 2b clinical study in DLB which began in the first quarter of 2023.
  • Net Loss: Net Loss was $2.2 million for the year ended December 31, 2023, compared to a net loss of $5.8 million for year ended December 31, 2022.

BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K

Retrieved on: 
Monday, April 1, 2024
Administration, Annual report, B cell, Obesity, Development, Cell, Patent, Library, Visual analogue scale, Patient, DSM-IV codes, Data monitoring committee, Form 10-K, Security (finance), Functional, Adipocyte, Type 2 diabetes, Small business, Investment, Research and development, NOA, European Patent Convention, Safety, Infrared spectroscopy correlation table, Orthopaedic Research Society, Annual general meeting, Pharmaceutical industry

MELVILLE, N.Y., April 01, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage company focused on stem cell-based therapies, announced today the filing of its Form 10-K annual report with the Securities and Exchange Commission ("SEC") for the year ended December 31, 2023.

Key Points: 
  • MELVILLE, N.Y., April 01, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage company focused on stem cell-based therapies, announced today the filing of its Form 10-K annual report with the Securities and Exchange Commission ("SEC") for the year ended December 31, 2023.
  • The annual report can be accessed on the SEC's website at www.sec.gov , and on the Company's website at www.biorestorative.com under "SEC Filing" in the Investors and Media section.
  • A total of up to 99 eligible subjects will be enrolled at up to 16 clinical sites in the United States.
  • At December 31, 2023, BioRestorative had cash, cash equivalents and investments in marketable securities of $11.07 million.

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Innodata Inc. - INOD

Retrieved on: 
Sunday, March 31, 2024
Research, Innodata, News, Ext, LLP, AI, Nature, Complaint, Pomerantz, Research and development, Action Replay, Wolfpack, Court

NEW YORK, March 31, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Innodata Inc. (“Innodata” or the “Company”) (NASDAQ: INOD).

Key Points: 
  • NEW YORK, March 31, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Innodata Inc. (“Innodata” or the “Company”) (NASDAQ: INOD).
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • The class action concerns whether Innodata and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.